Stay updated with breaking news from Cogent research. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Deflationary europe feels than america. Francine this is also because the pandemic hit italy first, so in terms of curves, you are a couple of weeks ahead in europe. It is a different set of numbers. The packages and loans that european governments are giving is different from what the u. S. Is doing, largely because you are at different stages in europe compared to the u. S. We are looking for that leaders summit, more stimulus coming from the commission and probably to give a strong voice to the commission that europe is united and in solidarity with country most affected by the virus. Tom a lot of different opinions. We will talk to Dennis Gartman about how to fold in a weaker euro call with gold. Here is viviana hurtado. Viviana donald trump signed an executive order to curb immigration. Green cards are currently on hold. They allow foreigners to become permanent residents. The governor the president says that will limit compe ....
The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our condensed consolidated financial statements and related notes. | May 9, 2023 ....
Cogent Biosciences to Present at Jefferies Virtual Healthcare Conference 2021 News provided by Share this article Share this article CAMBRIDGE, Mass. and BOULDER, Colo., May 26, 2021 /PRNewswire/ Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew Robbins, Chief Executive Officer and President, will present at Jefferies Virtual Healthcare Conference on Thursday, June 3 rd, from 11:30-11:55am ET. Access to the webcast of this event, as well as an archived recording, will be available under the Events tab on the investor relations section of the Cogent Biosciences website at: https://investors.cogentbio.com/events. ....
Cogent Biosciences Provides Corporate Updates and Reports First Quarter 2021 Financial Results IND cleared for Phase 2 study of CGT9486, a selective mutant KIT inhibitor, in Advanced Systemic Mastocytosis patients John Robinson, PhD appointed as Chief Scientific Officer to lead newly created Cogent Research team Evan Kearns, JD joined Cogent as Chief Legal Officer Ended Q1 2021 with $230.7 million in cash, sufficient to fund operations into 2024 News provided by Share this article Share this article CAMBRIDGE, Mass. and BOULDER, Colo., May 12, 2021 /PRNewswire/ Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced financial results for the first quarter ended March 31, 2021 and provided several corporate updates. ....